CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
Primary Purpose
B-cell Leukemia
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
CD19/CD20 Dual-CAR-T cells
Sponsored by
About this trial
This is an interventional treatment trial for B-cell Leukemia
Eligibility Criteria
Inclusion Criteria:
Relapsed and refractory B-cell acute malignancies with:
- Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD≥0.1%);
- MRD≥0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or recurrence after complete remission or MRD ≥ 0.1% after HSCT;
- Refractory: at least two courses of chemotherapy did not achieve complete remission or MRD ≥ 0.1%;
- Patients must have evaluable evidence of disease, including minimal residual disease (MRD);
- Ph + patients who meet the following criteria can register:Failure to tolerate TKI or TKI treatment failure, or failure to transplant;
- Double positive expression of CD19 / CD20 in B cells;
- Ages 1 to 70 years, including boundary values;
- ECOG score 0-3 points;
- Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside.
- Patients who voluntarily sign informed consent and are willing to comply with treatment plans.
Exclusion Criteria:
patients with organ failure:
- Heart: NYHA heart function grade IV;
- Liver: Grade C that achieves Child-Turcotte liver function grading;
- Kidney: kidney failure and uremia;
- Lung: symptoms of respiratory failure;
- Brain: a person with a disability;
- Active infections that are difficult to control;
- Human immunodeficiency virus (HIV) positive;
- Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min;
- GVHD ≥ 2 or anti-GVHD treatment;
- Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion;
- Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1 week;
- Central nervous system white blood that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white blood cell count >15WBCs/mL);
- intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation;
- pregnant or lactating women;
- The patient does not agree to use effective contraception during the treatment period and for the next 3 months;
- Patients who participate in other clinical studies at the same time;
- The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.
Sites / Locations
- Hebei Yanda Ludaopei Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
CD19/CD20 Dual-CAR-T cells
Arm Description
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
Outcomes
Primary Outcome Measures
Percentage of participants with adverse events.
Objective remission rate(ORR)
The percentage of participants who achieved complete remission (CR) and partial remission over all participants.
Secondary Outcome Measures
Relapse-Free Survival(RFS )
Overall-Survival(OS)
Persistence of CAR-T cells in vivo
Full Information
NCT ID
NCT04260945
First Posted
February 6, 2020
Last Updated
March 6, 2022
Sponsor
Hebei Yanda Ludaopei Hospital
Collaborators
China Immunotech (Beijing) Biotechnology Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT04260945
Brief Title
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
Official Title
CD19/CD20 Dual-CAR-T for Patients With B-cell Leukemia
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
March 10, 2020 (Actual)
Primary Completion Date
October 10, 2021 (Actual)
Study Completion Date
February 10, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hebei Yanda Ludaopei Hospital
Collaborators
China Immunotech (Beijing) Biotechnology Co., Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell leukemia.
Detailed Description
This Phase I study is designed as a pilot trial evaluating the safety and efficacy of CD19/CD20 Dual-CAR-T cell therapy in subjects with refractory and relapsed B cell leukemia. Subjects will receive cytoreductive chemotherapy with cyclophosphamide and fludarabine on days -5, -4 and -3 followed by infusion of CD19/CD20 Dual-CAR-T cells. Safety and efficacy of CD19/CD20 Dual-CAR-T cells therapy will be monitored. The purpose of current study is to determine the clinical efficacy and safety of CD19/CD20 Dual-CAR-T cells therapy in patients with refractory and relapsed B-cell leukemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
B-cell Leukemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
CD19/CD20 Dual-CAR-T cells
Arm Type
Experimental
Arm Description
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
Intervention Type
Biological
Intervention Name(s)
CD19/CD20 Dual-CAR-T cells
Intervention Description
CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 0.6-3×106 cells/kg.
Primary Outcome Measure Information:
Title
Percentage of participants with adverse events.
Time Frame
6 months
Title
Objective remission rate(ORR)
Description
The percentage of participants who achieved complete remission (CR) and partial remission over all participants.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Relapse-Free Survival(RFS )
Time Frame
6 months
Title
Overall-Survival(OS)
Time Frame
6 months
Title
Persistence of CAR-T cells in vivo
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Relapsed and refractory B-cell acute malignancies with:
Relapsed after competed remission, could not get competed remission after at more than 1 course of chemotherapy (including MRD≥0.1%);
MRD≥0.1% after allogeneic hematopoietic stem cell transplantation(HSCT), or recurrence after complete remission or MRD ≥ 0.1% after HSCT;
Refractory: at least two courses of chemotherapy did not achieve complete remission or MRD ≥ 0.1%;
Patients must have evaluable evidence of disease, including minimal residual disease (MRD);
Ph + patients who meet the following criteria can register:Failure to tolerate TKI or TKI treatment failure, or failure to transplant;
Double positive expression of CD19 / CD20 in B cells;
Ages 1 to 70 years, including boundary values;
ECOG score 0-3 points;
Women of childbearing age (15-49 years old) must receive a pregnancy test within 7 days prior to initiation of treatment and the results are negative; male and female patients with fertility must use an effective contraceptive to ensure 3 months after discontinuation of treatment during the study period not pregnant inside.
Patients who voluntarily sign informed consent and are willing to comply with treatment plans.
Exclusion Criteria:
patients with organ failure:
Heart: NYHA heart function grade IV;
Liver: Grade C that achieves Child-Turcotte liver function grading;
Kidney: kidney failure and uremia;
Lung: symptoms of respiratory failure;
Brain: a person with a disability;
Active infections that are difficult to control;
Human immunodeficiency virus (HIV) positive;
Liver and kidney function: total bilirubin > 5 × ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 5 × ULN, serum creatinine clearance rate 60mL / min;
GVHD ≥ 2 or anti-GVHD treatment;
Received allogeneic cell therapy within 4 weeks, such as donor lymphocyte infusion;
Subject received anti-tumor treatment (chemotherapy, mAb, or hormone) for less than 1 week;
Central nervous system white blood that is symptomatic or uncontrolled by systemic chemotherapy and intrathecal chemotherapy (a large number of tumor cells in CSF, white blood cell count >15WBCs/mL);
intracranial hypertension or unconsciousness; respiratory failure; diffuse vascular internal coagulation;
pregnant or lactating women;
The patient does not agree to use effective contraception during the treatment period and for the next 3 months;
Patients who participate in other clinical studies at the same time;
The investigator believes that there are other factors that are not suitable for inclusion or influence the subject's participation or completion of the study.
Facility Information:
Facility Name
Hebei Yanda Ludaopei Hospital
City
Sanhe
State/Province
Hebei
ZIP/Postal Code
065200
Country
China
12. IPD Sharing Statement
Learn more about this trial
CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients
We'll reach out to this number within 24 hrs